Natural and synthetic compounds for glioma treatment based on ros-mediated strategy
YF Wang, JY Hu - European Journal of Pharmacology, 2023 - Elsevier
Glioma is the most frequent and most malignant tumor of the central nervous system (CNS),
accounting for about 50% of all CNS tumor and approximately 80% of the malignant primary …
accounting for about 50% of all CNS tumor and approximately 80% of the malignant primary …
[HTML][HTML] Regulation of IGFBP-2 expression during fasting
Insulin-like growth factor (IGF)-binding protein-2 (IGFBP-2), one of the most abundant
circulating IGFBPs, is known to attenuate the biological action of IGF-1. Although the effect of …
circulating IGFBPs, is known to attenuate the biological action of IGF-1. Although the effect of …
Differential effects of microRNAs on glioblastoma growth and migration
D Jeansonne, M Pacifici, A Lassak, K Reiss, G Russo… - Genes, 2013 - mdpi.com
Glioblastoma multiforme is characterized by rapid proliferation, aggressive metastatic
potential, and resistance to radio-and chemotherapy. The matricellular protein CYR61 …
potential, and resistance to radio-and chemotherapy. The matricellular protein CYR61 …
Deconvolution and network analysis of IDH-mutant lower grade glioma predict recurrence and indicate therapeutic targets
G Li, Y Jiang, X Lyu, Y Cai, M Zhang, Z Wang, G Li… - …, 2019 - Taylor & Francis
Aim: IDH-mutant lower grade glioma (LGG) has been proven to have a good prognosis.
However, its high recurrence rate has become a major therapeutic difficulty. Materials & …
However, its high recurrence rate has become a major therapeutic difficulty. Materials & …
Resistance to antiangiogenic treatments: a review
T Koltai, SJ Reshkin, RA Cardone - Antiangiogenic Drugs as …, 2022 - Elsevier
Angiogenesis (blood vessel formation) is essential for tissue growth in both normal
development and physiology and in some diseases such as inflammation and cancer …
development and physiology and in some diseases such as inflammation and cancer …
[HTML][HTML] Repurposing of metabolic drugs and mitochondrial modulators as an emerging class of cancer therapeutics with a special focus on breast cancer
V Tripathi, P Jaiswal, K Sahu, SK Majumder… - Advances in Cancer …, 2022 - Elsevier
Background As per facts sheet of WHO, cancer is a leading cause of mortality worldwide
accounting nearly 10 million deaths in 2020. However, breast, lung, colon and rectum …
accounting nearly 10 million deaths in 2020. However, breast, lung, colon and rectum …
Fenofibrate interferes with the diapedesis of lung adenocarcinoma cells through the interference with Cx43/EGF-dependent intercellular signaling
K Piwowarczyk, E Kwiecień, J Sośniak, E Zimoląg… - Cancers, 2018 - mdpi.com
Extravasation of circulating cancer cells is regulated by the intercellular/intracellular
signaling pathways that locally impair the endothelial barrier function. Co-cultures of human …
signaling pathways that locally impair the endothelial barrier function. Co-cultures of human …
[PDF][PDF] Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1
Adjuvant-induced arthritis is a chronic inflammatory illness that induces muscle wasting and
decreases circulating IGF1. Eicosapentaenoic acid (EPA) and fenofibrate, a peroxisome …
decreases circulating IGF1. Eicosapentaenoic acid (EPA) and fenofibrate, a peroxisome …
Fenofibrate in cancer: Mechanisms involved in anticancer activity
T Koltai - F1000Research, 2015 - f1000research.com
Objective: To review the mechanisms of anti-cancer activity of fenofibrate (FF) and other
Peroxisome Proliferator Activator Receptor α (PPARα) agonists based on evidences …
Peroxisome Proliferator Activator Receptor α (PPARα) agonists based on evidences …
[PDF][PDF] Peroxisome Proliferator-Activated Receptors and the Hallmarks of Cancer. Cells 2022, 11, 2432
N Wagner, KD Wagner - 2022 - researchgate.net
Peroxisome proliferator-activated receptors (PPARs) function as nuclear transcription factors
upon the binding of physiological or pharmacological ligands and heterodimerization with …
upon the binding of physiological or pharmacological ligands and heterodimerization with …